Imunon, Inc.
NASDAQ: IMNN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stacy R. Lindborg
- Employees
- 25
- Headquarters
- Lawrenceville, United States
- IPO year
- 1999
- Market cap
- $4.4M
- Website
- https://www.imunon.com
Loading IMNN…
Loading profile data…Frequently asked questions about IMNN
What does Imunon, Inc. (IMNN) do?
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-acti...
Where does IMNN trade?
Imunon, Inc. (IMNN) trades on the NASDAQ Capital Market.
What sector is IMNN in?
Imunon, Inc. (IMNN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Imunon, Inc.?
Stacy R. Lindborg is the chief executive officer of Imunon, Inc. (IMNN).
Where is Imunon, Inc. headquartered?
Imunon, Inc. is headquartered in United States.
Does IMNN pay a dividend?
Imunon, Inc. (IMNN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMNN go public?
Imunon, Inc. (IMNN) completed its initial public offering in 1999.